Columns & Departments
Drug & Device News
Bellwether Trial Opening in Vaginal Mesh MDL <br>NuvaRing Settlement in the Works
Features
New Jersey Case Study
There has been a lack of consistency in malpractice cases where the plaintiff has settled with one or more defendants, and then goes to trial against other defendants. However, a recently published New Jersey Law Division case has brought a measure of consistency to this issue.
Features
New Jersey Manufacturers and Punitive Damages
As discussed in Part One of this article, New Jersey's Products Liability Act (Defective Product) (PLA), N.J. Stat. ' 2A:58C-5 (c) (2013), prevents injured plaintiffs seeking compensation from drug and device manufacturers from being awarded punitive damages. The statute, which in an earlier form was enacted in 2008, provides, in pertinent part:
Columns & Departments
Drug & Device News
Discussion of news and litigation.
Columns & Departments
Med Mal News
Recent news items of importance.
Features
Judicial Scrutiny of 'Other Insurance' Clauses
Conclusion of a discussion of the ways in which different jurisdictions treat "excess insurance" clauses ' those that describe an insurer's obligation when more than one insurance policy provides coverage to the same insured for the same loss.
Features
OCD: Beware Misdiagnosis
In the case of the diagnosis of "obsessive compulsive disorder" (OCD), a misdiagnosis may send the patient down the wrong treatment path entirely.
Features
New Jersey Manufacturers and Punitive Damages
The state of New Jersey is home to the headquarters of 17 of the top 20 drug-producing companies in the world. These include pharmaceuticals producers Wyeth, Merck and Co. and Johnson & Johnson.
Columns & Departments
Verdicts
Rulings of interest and importance to med mal attorneys.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- The DOJ's New Parameters for Evaluating Corporate Compliance ProgramsThe parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.Read More ›
- Bankruptcy Sales: Finding a Diamond In the RoughThere is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.Read More ›
- The DOJ's Corporate Enforcement Policy: One Year LaterThe DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.Read More ›
- The DOJ's Latest Opioid Crime-Fighting Tool: The Civil False Claims Act<b><i>The U.S. Department of Justice Is Now Using The False Claims Act — Traditionally a Civil Enforcement Tool — to Combat the United States' Sweeping Opioid Epidemic</b></i><p>The use of the FCA is part of a larger DOJ strategy to develop multi-faceted solutions for this public health emergency.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›
